ArticleNeuroepidemiology2026
Global Statistics of Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, and Conduct Disorder among School-Age Children from 1990-2021, with Forecasts to 2040.
Article in Neuroepidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMental disorders among school-age children represent a significant global health issue and substantially contribute to the global disease burden. This study aimed to examine the patterns and trends of attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and conduct disorder (CD), which are commonly observed in school-age children, from 1990 to 2021, offering valuable insights for health policy formulation, medical resource allocation, and optimization of patient management strategies.
methodsWe analyzed data from the Global Burden of Disease (GBD) 2021 study for 21 regions and 204 countries, focusing on prevalence, disability-adjusted life years (DALYs), gender, and different time periods to gain a deeper understanding of the health burden. We assessed correlations with the Socio-demographic Index (SDI) and employed autoregressive integrated moving average modeling to forecast developments up to 2040, enabling us to better comprehend the burden and trends of these mental disorders.
resultsIn 2021, the prevalence rates of ADHD, ASD, and CD per 100,000 population among children aged 5-14 years were 2,374.8, 847.13, and 2,146.48, respectively; DALY rates were 29.17, 162.85, and 262.53, respectively. Compared to 1990, prevalence and DALY rates exhibited changes of -0.06, 0.03, and 0.04, respectively. Australia, Japan, and the UK exhibited particularly notable burdens, with the UK continuing to show rapid growth in ASD, while ADHD and CD increased rapidly in China and India, respectively. Gender and age analyses revealed a higher burden among males. Regions with high SDI displayed higher epidemiological indicators. For the 2040 forecast, the indicators for ADHD in terms of prevalence and DALYs are projected to be 3,796.65 and 44.33 for males, and 1,343.18 and 16.23 for females. For ASD, they are projected to be 1,103.04 and 215.23 for males, and 552.01 and 106.40 for females. For CD, they are projected to be 2,650.69 and 325.64 for males, and 1,593.57 and 200.41 for females.
conclusionThis study underscores the complex epidemiological landscape of ADHD, ASD, and CD, revealing variations in burden across gender and geographical regions. It emphasizes the urgent need for healthcare professionals and policymakers to devise innovative prevention and healthcare strategies based on the current and evolving burden of these mental disorders, with the aim of alleviating the global disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.